Bristol Myers Squibb Submits New Indication Application for PD-1 Inhibitor Nivolumab in China, Likely for Hepatocellular Carcinoma
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
Screenshot source: CDE official website
A Phase 3 Clinical Trial Comparing Nivolumab Plus Ipilimumab with Sorafenib or Lenvatinib as First-Line Treatment for Advanced Hepatocellular CarcinomaCTR20192560 ）； A Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (CTR20200050 ）； And a Phase 2 clinical trial evaluating its LAG-3 antibody Relatlimab in combination with Nivolumab for patients with advanced hepatocellular carcinoma who have not previously received immunooncology therapy and progressed after tyrosine kinase inhibitor treatment (CTR20221168 ）。
Globally, since its initial approval in 2014, the number of approved indications for Nivolumab has continued to increase.To date, the drug has been approved for marketing in dozens of countries and regions worldwide, with indications covering lung cancer, head and neck cancer, gastric cancer, esophageal cancer, liver cancer, renal cancer, colorectal cancer, urothelial carcinoma, melanoma, Hodgkin's lymphoma, pleural tumors, and other cancers.Type。
Since its launch, the sales of Nivolumab have been on the rise, with global sales reaching $8.249 billion in 2022. In 2023, it maintained an upward trend, reaching $9.009 billion, remaining one of the main sources of revenue for Bristol-Myers Squibb.
Image Source: Insight Database Web Version
